Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 30Active not recruiting 12Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

TIC10 compound 3trastuzumab deruxtecan 2umbralisib 1ublituximab 1pembrolizumab 1infigratinib 1enfortumab vedotin 1duvelisib 1blinatumomab 1belumosudil 1Rituximab 1KD025 1Gemcitabine 1Crizotinib 1Cisplatin 1Carboplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Has announcements × pembrolizumab × Clear all
NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡